Sequoia genetics Co. Ltd. announced the beginning of clinical trials of diagnostic system for severe hereditary diseases detection in newborns and carrier state in couples planning a family. The developed molecular genetic solution is based on next generation sequencing (NGS) technology and consists of reagents kits and specialized software. Since the solution is designed for the mutation detection in clinics a special attention has been given to the issue of traceability and unambiguity of sequencing results in order to ensure the accuracy and reproducibility of the assay. To provide extensive clinical trials Sequoia genetics established partnership with several European laboratories: Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP, Portugal), StabVida company (Portugal) and the Center for Genome Research at the University of Liverpool (UK).

The 38th Congress of European Biochemical Societies Federation - one of the most representative events for demonstration of latest achievements in field of fundamental biochemical sciences - will be held in St. Petersburg in July 6-11.